{"date":"2025-10-26","count":2,"source":"公開資訊觀測站（MOPS）","attribution":"引用請註明：Drugnews 事實帳本（https://drugnews.com.tw/filings/）與公開資訊觀測站原始公告","records":[{"id":"tw-4157-2025-10-26-2132-pg7z5","company_id":"4157","company":"太景*-KY","market":"上櫃","industry":"生技醫療","date":"2025-10-26","time":"21:32:41","subject":"公告本公司接獲合作夥伴健康元藥業集團通知抗流感病毒新藥Pixavir marboxil (TG-1000)獲中國大陸國家藥品監督管理局（NMPA）同意進行小兒劑型三期臨床試驗。","clause":"第10款","fact_date":"2025-10-23","cite_as":"公開資訊觀測站重大訊息：太景*-KY（4157），2025-10-26 21:32，「公告本公司接獲合作夥伴健康元藥業集團通知抗流感病毒新藥Pixavir marboxil (TG-1000)獲中國大陸國家」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6892-2025-10-26-1601-1gujaw9","company_id":"6892","company":"台寶生醫","market":"興櫃","industry":"生技醫療","date":"2025-10-26","time":"16:01:53","subject":"台寶生醫調節型T細胞二期臨床試驗於美國完成首位病患收案","clause":"第44款","fact_date":"2025-10-24","cite_as":"公開資訊觀測站重大訊息：台寶生醫（6892），2025-10-26 16:01，「台寶生醫調節型T細胞二期臨床試驗於美國完成首位病患收案」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"}]}